My posts are opinions, and are not an investment advice. Reposted or liked content does not mean I agree with or support that content. Daily reminder - YOLO.
@ElieJarrougeMD You should have done treadmill stress test. I personally think he needs statins. Looks like familial hyper cholestrol. Intern med doc cannot substitute for a cardiologist.
@DavidDin That big rise to ~$40 was based on hope that potential Covid vaccine of IBRX could get funding from op warp speed. Didn't happen. MRNA Covid shots got EUA, IBRX collapsed. Patrick was busy in showmanship, investors lost money in my opinion. Anktiva is terrific drug, IBRX mgmt nah
@aakashgupta Anktiva is the next Keytruda. I've been researching this company since 2020 before it was merged with another listed PSS's company called Nantkwest. It was working on a Covid vaccine but PSS was busy being a showman on TV rather than a scientist in the lab. @adamfeuerstein
@adamfeuerstein@aakashgupta $IBRX in my opinion will announce PIPE by some major insti investor about $300M to $500M, could be PIF - Saudi SWF or the likes, to start new trials, Anktiva label expansion, as well as accelerate current trials, commercial activities for Anktiva in EU. Has cash expense $80M/qtr.
@Scooter0732@Tradelearner022 Anktiva is a subcutaneous drug, not an IV infusion. For NMIBC it's given intravesically mixed with BCG. Get your facts right rather than spreading FUD.
@adamfeuerstein@DrPatrick Saudi has a large adult population that smokes cigg, so more lung/bladder cancer cases. They're looking for a drug that has greater % of complete response outcomes, not just OS. Anktiva best works alongside a vaccine that exposes cancer antigen to immune system. Ofcourse revenues
@NileshShah68 Nilesh bhai @NileshShah68 it's written in the Bloomberg chart itself (top left corner) - MXCN Index. You should have blacked it out to hide.
@DrPatrick Hi Dr
Best time to convert $IBRX debt from Nant entities to grants and make IBRX almost debt free. This will raise the share price sharply ($10+) and you can raise $200M equity at $5B+ valuations to accelerate trials. Shorts gonna pulverize @bullishbruk@ImmunityBio@ericjackson
@BillAckman@elonmusk@SpaceX@SECGov@Tesla In my opinion, this is putting TSLA stock on steroids, manipulating TSLA share price. Looks like a hand in glove deal with musk with the end goal of making @elonmusk the first trillionaire. Get a life Bill, you lack spine.
@bullishbruk Wake up!
There's no P3 being conducted for lymphopenic. Although Anktiva is a good candidate, trial designs have been pathetic. I don't know if Dr Soon-Shiong listens to trial design experts or dictates what he wants. To me he looks more like a showman than a biotech innovator.
@ericjackson I believe in the $OPEN stock. But if you keep promoting BTC that crashed 35% even when mkt is at all time high, people will start losing trust in you. Will erode your reputation. Stick to $OPEN.
I'll give you a stock that could 100x, $ANVS. DM me for details I'm a biotech analyst
@Tiggersdad2@founderwithadhd You partly answer your own question. "Scale" the biggest differentiator.
The other differentiators being
1. Their propereitary data and the
AI code based on that data
2. First Mover Advantage
3. Stupendous leadership with
very large skin in the game.